Early Detection of Alzheimer’s Using Hyperspectral Retinal Imaging with Eliav Shaked and Catherine Bornbaum RetiSpec TRANSCRIPT
Download PDFMar 3, 2022
Eliav Shaked, CEO, and Catherine Bornbaum, Head of Clinical Operations and Partnerships at RetiSpec are using hyperspectral retinal imaging to find more accurate and earlier biomarkers of neurodegenerative diseases. As part of a regular eye exam, this non-invasive test can be administered by an ophthalmologist or optometrist using existing retinal cameras with the data being analyzed using AI to identify unique molecule signatures.
Eliav explains, "What's unique about hyperspectral imaging or specifically hyperspectral retinal imaging is the fact that it's a tool that measures different coloring of elements in a much more detailed way. So, while we humans are limited to seeing and interpreting only three colors, hyperspectral retinal imaging can cover more than a hundred different colors in a very precise way. And it's really our way to get much more content from the back of the eye. And what RetiSpec is doing with that data is we're integrating our very own artificial intelligence that allows us to recognize patterns that no human eye can see."
Catherine elaborates, "We are focused right now on identifying the markers for Alzheimer's disease through this hyperspectral retinal imaging. But because of the close connection between the retina and the brain, we believe that there are also a number of other indications and specifically neurologic conditions that can be detected using this approach for things like ALS, MS, Parkinson's disease, CTE, and a number of conditions."
@RetiSpec @EliavShaked @CathBornbaum #RetiSpec #EarlyAlzheimersDetection #AlzheimersDisease #RetinalScans #HyperspectralImaging
